Achillion ACH471-201

Brief description of study

A randomized, placebo-controlled, double-blinded (sponsor-open) study with six months of dosing. The study will include approximately 20 patients with C3 glomerulopathy who have not undergone renal transplant. Patients will be randomized 1:1 to ACH-0144471 or placebo. The randomization will be stratified by the disease diagnosis: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN).


Clinical Study Identifier: s16-02046
ClinicalTrials.gov Identifier: NCT03369236
Principal Investigator: Howard Trachtman
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.